Company Updates

Total Blood Profile has had a third patent granted for our rapid diagnostic tests in the US

Sydney, 20 December 2019 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the results of its Extraordinary General

Private Funding Secured to complete MVP. Secured working with Martin Place Securities in Sydney. The first company to use Pawn Broker’s Act to support digital lending.

Essential Queensland (EQ) is proud to announce Ken Richards is the newest member of our board and will be appointed the new chairman for Essential Queensland.

The Collins St Value continues to perform strongly with the unit price up 3.58% after fees for the month of November.
A combination of portfolio holdings across multiple sectors drove returns through

MAAS Solutions software development has officially kicked off on 13/11/2019 and expected delivery of MVP for 2 workable modules are March 2020.

KAZIA INITIATES PREPARATORY ACTIVITIES TO BRING GDC-0084 INTO
GBM AGILE, AN INTERNATIONAL PHASE II / III STUDY IN GLIOBLASTOMA

Alvant is a leader in the design and manufacture of Aluminium Matrix Composite (AMC) materials.

DroneShield Ltd (ASX:DRO or DRO.AU) (“DroneShield” or the “Company”) is pleased to report the combined elements of the Presidential Security Group (PSG) and PHISGOC Games Safety & Security Counter-Dro